ArticleFrontiers in oncology2026
A decade of receptor discordance and phenotypic transitions in metastatic breast cancer: a single-center retrospective study of 363 cases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate real-world changes in the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and corresponding molecular subtypes in primary and metastatic breast cancer, as well as their influencing factors and impact on prognosis. Methods: This retrospective study analyzed 436 paired lesion samples of primary and metastatic breast cancer treated between 2013 and 2023. Statistical evaluation was conducted to examine receptor discordance (ER, PR, HER2) and clinicopathological correlations. Result: Receptor discordance rates between primary and metastatic lesions were 25.1% for ER, 33.3% for PR, 32.8% for HER2, and 33.8% for molecular subtypes. PR showed the highest discordance, frequently transitioning from positive to negative. ER discordance predominantly involved the loss of low expression. HER2 discordance was highest in liver metastases (59.3%). Molecular subtype changes were most common in HR+/HER2- tumors (42.6%). ER discordance correlated with neoadjuvant chemotherapy and endocrine therapy, while HER2 discordance was linked to targeted therapy and lung metastases. Loss of hormone receptor (HR) or HER2 expression was associated with poorer overall survival (OS) (HR: median OS 95 vs. 70 months, P = 0.0018; HER2: median OS 78 vs. 68 months, P = 0.025). Conversely, sustained or acquired HR/HER2 positivity improved OS. Conclusions: Heterogeneity in ER, PR, HER2, and molecular subtype expression significantly influences prognosis and treatment outcomes in metastatic breast cancer. Reassessment of receptor status in metastatic lesions is essential for optimizing individualized treatment strategies and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.